• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    3/5/21 1:30:27 PM ET
    $SNSS
    Major Pharmaceuticals
    Health Care
    Get the next $SNSS alert in real time by email
    SC 13G/A 1 lvp_sc13ga.htm FORM SC 13G AMENDMENT 1

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Schedule 13G/A

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)

    (Amendment No. 1)*

     

    Viracta Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    92765F108

    (CUSIP Number)

     

    February 25, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [_]Rule 13d-1(b)

    [_]Rule 13d-1(c)

    [X]Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Continued on following pages)

     

     

     

     

     

      

     

    Page 2 of 12

     

    1 NAME OF REPORTING PERSONS           LVP Life Science Ventures III, L.P. (“LVP III”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [_] (b) [X]

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    2,901,152 shares, except that LVP GP III, LLC (“GP III”), the general partner of LVP III, may be deemed to have sole power to vote these shares, and Patrick Latterell (“Latterell”), the managing member of GP III, may be deemed to have shared power to vote these shares.
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    2,901,152 shares, except that GP III, the general partner of LVP III, may be deemed to have sole power to dispose of these shares, and Latterell, the managing member of GP III, may be deemed to have shared power to dispose of these shares.
    8 SHARED DISPOSITIVE POWER
    See response to row 7.
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,901,152

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [_]

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    7.84%

    12

    TYPE OF REPORTING PERSON

    PN

           

     

     

      

     

    Page 3 of 12

     

    1 NAME OF REPORTING PERSONS           LVP III Associates, L.P. (“Associates”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [_] (b) [X]

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    145,055 shares, except that GP III, the general partner of Associates, may be deemed to have sole power to vote these shares, and Latterell, the managing member of GP III, may be deemed to have shared power to vote these shares.
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    145,055 shares, except that GP III, the general partner of Associates, may be deemed to have sole power to dispose of these shares, and Latterell, the managing member of GP III, may be deemed to have shared power to dispose of these shares.
    8 SHARED DISPOSITIVE POWER
    See response to row 7.
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    145,055

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [_]

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    0.39%

    12

    TYPE OF REPORTING PERSON

    PN

           

     

     

     

      

     

    Page 4 of 12

     

    1 NAME OF REPORTING PERSONS           LVP III Partners, L.P. (“Partners”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [_] (b) [X]

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    72,526 shares, except that GP III, the general partner of Partners, may be deemed to have sole power to vote these shares, and Latterell, the managing member of GP III, may be deemed to have shared power to vote these shares.
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    72,526 shares, except that GP III, the general partner of Partners, may be deemed to have sole power to dispose of these shares, and Latterell, the managing member of GP III, may be deemed to have shared power to dispose of these shares.
    8 SHARED DISPOSITIVE POWER
    See response to row 7.
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    72,526

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [_]

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    0.20%

    12

    TYPE OF REPORTING PERSON

    PN

           

     

     

     

      

     

    Page 5 of 12

     

    1 NAME OF REPORTING PERSONS           LVP GP III, LLC (“GP III”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [_] (b) [X]

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    3,118,733 shares, of which 2,901,152 are directly owned by LVP III, 145,055 of which are directly owned by Associates and 72,526 of which are directly owned by Partners.  GP III, the general partner of LVP III, Associates and Partners, may be deemed to have sole power to vote these shares, and Latterell, the managing member of GP III, may be deemed to have shared power to vote these shares.
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    3,118,733 shares, of which 2,901,152 are directly owned by LVP III, 145,055 of which are directly owned by Associates and 72,526 of which are directly owned by Partners.  GP III, the general partner of LVP III, Associates and Partners, may be deemed to have sole power to dispose of these shares, and Latterell, the managing member of GP III, may be deemed to have shared power to dispose of these shares.
    8 SHARED DISPOSITIVE POWER
    See response to row 7.
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,118,733

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [_]

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    8.43%

    12

    TYPE OF REPORTING PERSON

    OO

           

     

     

     

      

     

    Page 6 of 12

     

    1 NAME OF REPORTING PERSONS           LVPMC, LLC (“LVPMC”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [_] (b) [X]

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    5,361 shares.  Latterell, the manager of LVPMC, may be deemed to have sole power to vote these shares.
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    5,361 shares.  Latterell, the manager of LVPMC, may be deemed to have shared power to dispose of these shares.
    8 SHARED DISPOSITIVE POWER
    See response to row 7.
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,361

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [_]

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    0.01%

    12

    TYPE OF REPORTING PERSON

    OO

           

     

     

     

      

     

    Page 7 of 12

     

    1 NAME OF REPORTING PERSONS           Patrick F. Latterell (“Latterell”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [_] (b) [X]

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    5,361 shares, all of which are directly owned by LVPMC, LLC. Latterell is the manager of LVPMC, LLC and may be deemed to have sole power to vote those shares.
    6 SHARED VOTING POWER
    3,118,733 shares, of which 2,901,152 are directly owned by LVP III, 145,055 of which are directly owned by Associates and 72,526 of which are directly owned by Partners.  Latterell is the managing member of GP III, which is the general partner of LVP III, Associates and Partners. Latterell may be deemed to have shared power to vote these shares.
    7 SOLE DISPOSITIVE POWER
    5,361 shares, all of which are directly owned by LVPMC, LLC.  Latterell is the manager of LVPMC, LLC and may be deemed to have sole power to dispose of those shares.
    8 SHARED DISPOSITIVE POWER
    3,118,733 shares, of which 2,901,152 are directly owned by LVP III, 145,055 of which are directly owned by Associates and 72,526 of which are directly owned by Partners.  Latterell is the managing member of GP III, which is the general partner of LVP III, Associates and Partners.  Latterell may be deemed to have shared power to dispose of these shares.
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,124,094

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [_]

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    8.44%

    12

    TYPE OF REPORTING PERSON

    IN

           

     

     

     

      

     

    Page 8 of 12

     

    ITEM 1(A).NAME OF ISSUER
      
     Viracta Therapeutics, Inc. (the “Issuer”)

     

    ITEM 1(B).ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES
      
     2533 S. Coast Hwy 101, Suite 210
     Cardiff, CA 92007

     

    ITEM 2(A).NAME OF PERSONS FILING
      
     This Schedule is filed by LVP Life Science Ventures III, L.P., a Delaware limited partnership, LVP III Associates, L.P., a Delaware limited partnership (“Associates”), LVP III Partners, L.P., a Delaware limited partnership (“Partners”), LVP GP III, LLC, a Delaware limited liability company (“GP III”), LVPMC, LLC, a Delaware limited liability company (“LVPMC”), and Patrick Latterell (“Latterell”). The foregoing entities and individuals are collectively referred to as the “Reporting Persons.”
      
    ITEM 2(B).ADDRESS OF PRINCIPAL OFFICE
      
     The address for each of the Reporting Persons is:
      
     

    c/o LVPMC, LLC

    2603 Camino Ramon, Suite 200

    San Ramon, CA 94583

     

    ITEM 2(C).CITIZENSHIP
      
     See Row 4 of cover page for each Reporting Person.

     

    ITEM 2(D).TITLE OF CLASS OF SECURITIES
      
     Common Stock, $0.0001 par value

     

    ITEM 2(E).CUSIP NUMBER
      
     92765F108

     

    ITEM 3.If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
      
     Not applicable.

     

    ITEM 4.OWNERSHIP
      
     The following information with respect to the ownership of the ordinary shares of the Issuer by the persons filing this Statement is provided as of February 25, 2021:

     

    (a)Amount beneficially owned:

    See Row 9 of cover page for each Reporting Person.

     

     

     

     

      

     

    Page 9 of 12

      

    (b)Percent of Class:

    See Row 11 of cover page for each Reporting Person.

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote:

    See Row 5 of cover page for each Reporting Person.

     

    (ii)Shared power to vote or to direct the vote:
       
      See Row 6 of cover page for each Reporting Person.

     

    (iii)Sole power to dispose or to direct the disposition of:
       
      See Row 7 of cover page for each Reporting Person.

     

    (iv)Shared power to dispose or to direct the disposition of:
       
      See Row 8 of cover page for each Reporting Person.

     

    ITEM 5.OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      
     Not applicable.

     

    ITEM 6.OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
      
     Under certain circumstances set forth in the limited partnership agreements of LVP III, Associates and Partners and the limited liability company agreement of GP III, the partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from the sale of, shares of the Issuer owned by each such entity of which they are a partner or member.

     

    ITEM 7.IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
      
     Not applicable.

     

    ITEM 8.IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
      
     Not applicable.

     

    ITEM 9.NOTICE OF DISSOLUTION OF GROUP.
      
     Not applicable.

     

    ITEM 10.CERTIFICATION.
      
     Not applicable.

     

     

     

      

     

    Page 10 of 12

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: March 3, 2021

     

    LVP LIFE SCIENCE VENTURES III, L.P.

     

    By:       LVP GP III, LLC

    Its:       General Partner

     

    By: /s/ Patrick F. Latterell                                 

    Name:    Patrick F. Latterell

    Its:          Managing Member

     

     

    LVP III ASSOCIATES, L.P.

     

    By:       LVP GP III, LLC

    Its:       General Partner

     

    By: /s/ Patrick F. Latterell                                 

    Name:    Patrick F. Latterell

    Its:          Managing Member

     

     

    LVP III PARTNERS, L.P.

     

    By:       LVP GP III, LLC

    Its:       General Partner

     

    By: /s/ Patrick F. Latterell                                 

    Name:    Patrick F. Latterell

    Its:          Managing Member

     

     

    LVP GP III, LLC

     

    By: /s/ Patrick F. Latterell                                 

    Name:    Patrick F. Latterell

    Its:          Managing Member

     

     

    LVPMC, LLC

     

    By: /s/ Patrick F. Latterell                                 

    Name:    Patrick F. Latterell

    Its:          Manager

     

     

    PATRICK F. LATTERELL

     

    By: /s/ Patrick F. Latterell                                 

    Name:    Patrick F. Latterell

     

     

      

     

    Page 11 of 12

     

    EXHIBIT INDEX

     

      Found on Sequentially
    Exhibit Numbered Page
       
    Exhibit A:  Agreement of Joint Filing 12
       

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

      

     

    Page 12 of 12

     

    exhibit A

     

    Agreement of Joint Filing

     

    The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the common stock of the Issuer shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G.

     

    Date: March 3, 2021

     

    LVP LIFE SCIENCE VENTURES III, L.P.

     

    By:       LVP GP III, LLC

    Its:       General Partner

     

    By: /s/ Patrick F. Latterell                                 

    Name:    Patrick F. Latterell

    Its:          Managing Member

     

     

    LVP III ASSOCIATES, L.P.

     

    By:       LVP GP III, LLC

    Its:       General Partner

     

    By: /s/ Patrick F. Latterell                                 

    Name:    Patrick F. Latterell

    Its:          Managing Member

     

     

    LVP III PARTNERS, L.P.

     

    By:       LVP GP III, LLC

    Its:       General Partner

     

    By: /s/ Patrick F. Latterell                                 

    Name:    Patrick F. Latterell

    Its:          Managing Member

     

     

    LVP GP III, LLC

     

    By: /s/ Patrick F. Latterell                                 

    Name:    Patrick F. Latterell

    Its:          Managing Member

     

     

    LVPMC, LLC

     

    By: /s/ Patrick F. Latterell                                 

    Name:    Patrick F. Latterell

    Its:          Manager

     

     

    PATRICK F. LATTERELL

     

    By: /s/ Patrick F. Latterell                                 

    Name:    Patrick F. Latterell

     

     

      

     

    Get the next $SNSS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SNSS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SNSS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sunesis Pharmaceuticals upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Sunesis Pharmaceuticals from Market Perform to Outperform and set a new price target of $12.00

      3/1/21 8:39:16 AM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • Sunesis Pharmaceuticals upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Sunesis Pharmaceuticals from Perform to Outperform and set a new price target of $12.00

      2/23/21 5:59:10 AM ET
      $SNSS
      Major Pharmaceuticals
      Health Care

    $SNSS
    SEC Filings

    See more
    • SEC Form 8-K filed

      8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)

      3/4/21 4:06:03 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • SEC Form 8-K filed

      8-K - SUNESIS PHARMACEUTICALS INC (0001061027) (Filer)

      2/24/21 4:34:51 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • SEC Form 10-K filed

      10-K - SUNESIS PHARMACEUTICALS INC (0001061027) (Filer)

      2/24/21 6:06:16 AM ET
      $SNSS
      Major Pharmaceuticals
      Health Care

    $SNSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by J. Barry Simon

      3 - Viracta Therapeutics, Inc. (0001061027) (Issuer)

      3/4/21 5:46:22 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • SEC Form 3 filed by Stephen Rubino

      3 - Viracta Therapeutics, Inc. (0001061027) (Issuer)

      3/4/21 5:42:13 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • SEC Form 3: Partnership Limited Fund 2 Amoon claimed ownership of 7,392,237 units of Common Stock

      3 - SUNESIS PHARMACEUTICALS INC (0001061027) (Issuer)

      2/25/21 6:09:20 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care

    $SNSS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma

      SAN DIEGO, Feb. 16, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 16/924,082. The allowed application, titled "Methods of Treating Virally Associated Cancers with Histone Deacetylase Inhibitors," describes the use of Viracta's all-oral combination product candidate of nanatinostat, the Company's proprietary investigational drug, and valganciclovir. The allowed claims cover the anticipated dose regimen to be advanced in the planned global registration trial for the trea

      2/16/21 8:00:00 AM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • Viracta Therapeutics to Participate in Upcoming Virtual Investor Conferences

      SAN DIEGO, Feb. 11, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the Company will participate in the upcoming LifeSci Partners Precision Oncology Day on February 17, 2021 and the 10th Annual SVB Leerink Global Healthcare Conference taking place February 22-26, 2021. The Company will present and participate in one-on-one investor meetings at both conferences. Details on the events can be found below. LifeSci Partners Precision Oncology Day Date: Wednesday, February 17, 2021 Time: 2:30 PM ET Format: Corporate presentation 10th Annual SVB Leerink Globa

      2/11/21 4:05:00 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of its Recent End of Phase 2 Meeting with the FDA

      SAN DIEGO, Dec. 7, 2020 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced recent clinical and regulatory developments regarding its lead program for the treatment of relapsed/refractory (R/R) EBV+ lymphomas. At the 62nd American Society of Hematology (ASH) Annual Meeting, Dr. Pierluigi Porcu of Sidney Kimmel Cancer Center, Thomas Jefferson University, presented updated data from Viracta's ongoing clinical trial evaluating its all-oral combination regimen of nanatinostat and valganciclovir for the treatment of patients with R/R EBV+ lymphoma that had failed one or more prior therapies

      12/7/20 8:30:00 AM ET
      $SNSS
      Major Pharmaceuticals
      Health Care

    $SNSS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed

      SC 13D/A - Viracta Therapeutics, Inc. (0001061027) (Subject)

      3/10/21 9:40:22 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Viracta Therapeutics, Inc. (0001061027) (Subject)

      3/8/21 5:05:56 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Viracta Therapeutics, Inc. (0001061027) (Subject)

      3/5/21 1:30:27 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care

    $SNSS
    Financials

    Live finance-specific insights

    See more
    • Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement

      Merger to create Nasdaq-listed company focused on developing Viracta’s precision oncology pipeline targeting virus-associated malignancies Registration trial for Viracta’s lead program in Epstein-Barr virus (EBV)-positive lymphomas expected to begin in the first half of 2021 Leading institutional investors committed a total of $105 million in private financings with Viracta Combined company expected to have approximately $120 million cash balance following the close of the merger Companies to host conference call today at 8:30 AM Eastern Time SOUTH SAN FRANCISCO and SAN DIEGO, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) and Viracta

      11/30/20 7:30:00 AM ET
      $SNSS
      Major Pharmaceuticals
      Health Care